New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
08:36 EDTAVNRAvanir Pharmaceuticals announces positive interim data from study with AVP-786
Avanir Pharmaceuticals announced that it has successfully completed the first of a two-stage pharmacokinetic study with AVP-786, a drug product containing a deuterium modified form of dextromethorphan. Based on interim data, Avanir believes that it has identified a formulation of AVP-786 with a comparable pharmacokinetic, safety and tolerability profile to AVP-923. The company has requested a meeting with the FDA to discuss the full development path for AVP-786. Avanir also announced today that the company intends to modify the enrollment target of its ongoing phase II clinical study of AVP-923 in central neuropathic pain in multiple sclerosis to 200 patients. As a result of this change, the company now expects to have data from the PRIME study in the fourth calendar quarter of 2013.
News For AVNR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 24, 2014
06:26 EDTAVNRAvanir 18.2M share Secondary priced at $11.00
Subscribe for More Information
September 23, 2014
06:12 EDTAVNRStocks with implied volatility below IV index mean; RAX AVNR
Subscribe for More Information
September 22, 2014
18:18 EDTAVNROn The Fly: After Hours Movers
Subscribe for More Information
16:41 EDTAVNRAvanir files automatic mixed securities shelf
11:02 EDTAVNROptions with decreasing implied volatility
Subscribe for More Information
06:17 EDTAVNRAvanir implied volatility of 91 at lower end of index mean range
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use